This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Mehra R , Zhu F , Yang DH , Cai KQ , Weaver J , Singh MK , Nikonova AS , Golemis EA , Flieder DB , Cooper HS , Lango M , Ridge JA , Burtness B
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers
Clin Cancer Res. 2013 Dec 1;19(23) :6633-43
AbstractPURPOSE: Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) pathway, of which ERCC1 is a rate-limiting element, are associated with cisplatin and possibly RT resistance. We have determined excision repair cross-complementing group 1 (ERCC1) expression in human papillomavirus (HPV)-negative SCCHN treated with surgery [+/- adjuvant radiotherapy/chemoradiation (CRT)]. EXPERIMENTAL DESIGN: We assessed ERCC1 protein expression in archival tumors using immunofluorescence staining and automatic quantitative analysis (AQUA) with three antibodies to ERCC1 (8F1, FL297, and HPA029773). Analysis with Classification and Regression Tree (CART) methods ascertained the cutoff points between high/low ERCC1 expression. Multivariable analysis adjusted for age, T, and N stage. Kaplan-Meier curves determined median survival. ERCC1 expression at initial tumor presentation and in recurrent disease were compared. Performance characteristics of antibodies were assessed. RESULTS: ERCC1 low/high groups were defined on the basis of AQUA analysis with 8F1/2009, FL297, and HPA029773. Among patients treated with surgery plus adjuvant radiotherapy/CRT, longer median survival was observed in ERCC1-low versus ERCC1-high tumors (64 vs. 29 months; P = 0.02; HPA029773). Data obtained with HPA029773 indicated no survival difference among patients treated only with surgery. Recurrent cancers had lower ERCC1 AQUA scores than tumors from initial presentation. Extensive characterization indicated optimal specificity and performance by the HPA029773 antibody. CONCLUSIONS: Using AQUA, with the specific ERCC1 antibody HPA029773, we found a statistical difference in survival among high/low-ERCC1 tumors from patients treated with surgery and adjuvant radiotherapy.
NotesMehra, Ranee Zhu, Fang Yang, Dong-Hua Cai, Kathy Q Weaver, Joellen Singh, Mahendra K Nikonova, Anna S Golemis, Erica A Flieder, Douglas B Cooper, Harry S Lango, Miriam Ridge, John A Burtness, Barbara CA06927/CA/NCI NIH HHS/United States CA63366/CA/NCI NIH HHS/United States R01 CA063366/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States Clin Cancer Res. 2013 Dec 1;19(23):6633-43. doi: 10.1158/1078-0432.CCR-13-0152. Epub 2013 Oct 2.